Marco G. Raddi

Florence, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.

Journal: Leukemia

Published: June 23, 2025

New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes.

New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: May 07, 2025

Biallelic SH2B3 germline variants are associated with a neonatal myeloproliferative disease and multisystemic involvement.

Biallelic SH2B3 germline variants are associated with a neonatal myeloproliferative disease and multisystemic involvement.

Journal: European journal of human genetics : EJHG

Published: January 09, 2025

IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score.

IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score.

Journal: Blood

Published: November 04, 2024

Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS.

Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS.

Journal: HemaSphere

Published: July 23, 2024

Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents.

Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents.

Journal: Blood cancer journal

Published: May 24, 2024

Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.

Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.

Journal: HemaSphere

Published: January 31, 2024

Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes.

Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes.

Journal: HemaSphere

Published: January 05, 2024

Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms.

Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms.

Journal: Leukemia

Published: November 29, 2023

A Nationwide Study of GATA2 Deficiency in Italy Reveals Novel Symptoms and Genotype-phenotype Association.

A Nationwide Study of GATA2 Deficiency in Italy Reveals Novel Symptoms and Genotype-phenotype Association.

Journal: Journal of clinical immunology

Published: June 05, 2023

PIEZO1 mutations impact on early clinical manifestations of myelodysplastic syndromes.

PIEZO1 mutations impact on early clinical manifestations of myelodysplastic syndromes.

Journal: American journal of hematology

Published: October 23, 2022

Showing 1-11 of 11

Last Updated: 09/26/2026